The tracker below provides information on accelerated assessment requests for planned marketing authorization applications (MAAs) that have come before the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
This latest update reflects among other things the fact that the planned MAAs for the following products have been granted accelerated assessment: